

11th Annual Vaccines World Summit 2021

Advancing vaccine business and technology to facilitate access to new vaccines and combat global pandemic threats in developing economies.

19 -20 May 2021 | VIRTUAL



VACCINES WORLD SUMMIT 2021 BRINGS YOU

500+
ATTENDEES

Including C-Suites, Heads/
VPs/Directors of Upstream &
Downstream Bioprocessing, R&D,
Quality & Compliance, Analytical
& more!

50+
ORGANIZATIONS

The Biggest Event Connecting You
to Vaccine Manufacturers from
Developing Economies such as India,
Indonesia, Thailand, South America,
and Africa.

50+
EXPERT SPEAKERS

Presentations on the Latest
Development in the COVID-19 Vaccine
Landscape. Co-Development
Opportunities, Process Development
know-how, Cost Reduction Strategies
to Maintain Competitiveness and more.

2+
DAYS OF NETWORKING

During the event and 4 weeks until
after. Engage in private 1 on 1 chats.
*6714 messages exchanged on the
event app in the past edition.



Rajinder Kumar Suri,
CEO, Developing Countries Vaccines
Manufacturers Network (DCVMN)



Matthew Downham,
Ph.D., Sustainable Manufacturing Lead, CEPI,
United Kingdom



Etleva Kadill,
Director Supply Division,
UNICEF, Denmark



Dominique Maugeais,
Vaccine Manufacturing Expert, GAVI,
Switzerland



Martin Friede,
Coordinator, Initiative for Vaccine Research
(IVR), WHO, Switzerland



Global Pandemic Vaccine Action Plan in Near- and Long-Term Strategies to Increase the Supply of Pandemic Vaccine to developing economies

DISTINGUISHED PANEL OF SPEAKERS



Keynote Presentation

Martin Friede,
Coordinator, Initiative for
Vaccine Research (IVR),
WHO, Switzerland



Keynote Presentation

Rajinder Kumar Suri,
CEO,
DCVMN



Keynote Presentation

Matthew Downham, PhD
Sustainable Manufacturing
Lead, CEPI,
United Kingdom



Keynote Presentation

Etleva Kadill,
Director Supply Division,
UNICEF, Denmark



Keynote Presentation

Dominique Maugeais,
Vaccine Manufacturing Expert,
GAVI, Switzerland



Raches Ella,

Project Lead: SARS-CoV-2
Vaccine,
Bharat Biotech, India



Scots Roberts,

Chief Scientific Officer,
Altimmune, USA



Li Shi,

CEO,
Shanghai Zerun
Biotechnology, China



Dr Anh Wartel,

Head of Clinical Development,
International Vaccine
Institute, Korea



Ofer Levy,

Director, Precision Vaccines Program,
Division of Infectious Diseases
Boston Children's Hospital
Professor, Harvard Medical School,
USA



Ashish Sahai,

Additional Director,
Serum Institute of India,
India



Ramesh Mathur,

Senior Vice President and Head,
Research and Development,
Biological E, India



Sanjay Singh,

CEO,
Gennova Pharmaceuticals,
India



Kapil Maitthil,

President & Head,
Vaccines and Diagnostics,
Zydis Cadila, India



Vickneshwaran Muthu

Senior Principal Assistant
Director,
Disease Control Division
Ministry of Health, Malaysia



Neelima Dwivedi,

Senior Director- External Affairs,
Market Access, Policy,
MSD, India



Dr. Harshad Patil,

Scientist, Interactive Research
School for Health Affairs, India



Dea Marsendah,

Hib Production, Bio Farma,
Indonesia



Jayesh Ranjan,

Principal Secretary, Industries &
Commerce (I&C) & Information
Technology (IT), Government of Telangana, India



Farshad Guirakhoo,

Chief Scientific Officer,
COVAXX and VAXXINITY,
USA



Remko van Leeuwen,

Project Coordinator,
INDIGO, Netherlands



Arun Kumar,

Preclinical Vaccines
Development Lead,
CEPI, Norway

3 Reasons why you should be at the Vaccines World Summit 2021

1

Map the future of the
Vaccines Landscape in
developing economies
with a special focus
on COVID-19 Vaccine
Development, Clinical
Trial Operations,
Cell Culture Process
Development and
Vaccines Manufacturing.

2

Gain insights on the next
generation platform for
vaccine development,
production, process
characterization, control,
and validation as well
as latest exclusive
insights on SARS- CoV-
2, Influenza, Zika,
Pneumococcal Vaccines.

3

Great opportunity
to connect and
explore partnership
and co-development
opportunities
with key vaccine
manufacturers
from developing
economies.

2021 SPONSORS & PARTNERS

SILVER SPONSOR



ASSOCIATE SPONSOR



ADVERTISING SPONSOR



SUPPORTED BY



**International
Vaccine
Institute**

IndiaAlliance
DBT wellcome



www.imbcams.ac.cn
IMBCAMS
中国医学科学院医学生物学研究所
奉献于人类健康事业



MEDIA PARTNERS



For Sponsorship Opportunities, Contact:

Pavithra Selvam

Project Manager

T: +65 3109 0225 | Email: pavithra.selvam@imapac.com

AGENDA AT A GLANCE

Conference Day 1	Conference Day 2
Pandemic Vaccine Case Studies and Vaccine Development	Vaccine Development and Manufacturing Excellence in Developing Economies
Morning Coffee Break	
SARS-CoV-2 Vaccine Development Case-studies and Challenges	Next Generation Platform Technologies and Clinical Trial Results from Next- Gen Pipelines in the Industry
Networking Lunch Break	
Pandemic Vaccine Panel and Clinical Trial Results from SARS-CoV-2 Vaccine Manufacturers	Vaccine Facilities of the Future
Afternoon Tea Break	
Fill & Finish and Vaccine Manufacturing in Developing Economies	Vaccine Manufacturing Excellence-Process Development, Production and Scale-up
Conference Ends	

For Speaking & Sponsorship Opportunities, Contact

Pavithra Selvam
Project Manager
pavithra.selvam@imapac.com
T: +65 3109 0225

CONFERENCE DAY 1 – 19TH MAY 2021

8:00	Conference Registration
9:00	IMAPAC' Welcome Remarks by Conference Producer
9:05	Chairman's Opening Remarks
	Pandemic Vaccine Case Studies and Vaccine Development
9:15	Precision Vaccine Approaches To Address The Coronavirus Pandemic - Safe and effective vaccines will key to overcoming the coronavirus pandemic. - Vaccine efficacy may vary with both the pathogen (eg, coronavirus variants) and with the host (eg, demographic features such as age) - In this context, precision vaccinology- i.e., the application of precision medicine principles to vaccine discovery and development will be key. To this end, the Precision Vaccines Program, based at Boston Children's Hospital, is employing cutting edge human in vitro modeling, adjuvant discovery and development as well as systems biology to advance next generation coronavirus vaccines targeted to distinct vulnerable populations such as the young and elderly. Ofer Levy, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital, Professor, Harvard Medical School, USA
10:00	Technology Presentation: Reserved for Vaccines Bioprocessing Solution Providers
10:25	AdCOVID elicits systemic and mucosal immunity against SARS-CoV-2 following single-dose intranasal administration - AdCOVID is based on the same intranasal adenoviral vector technology as their clinical stage vaccine candidates for anthrax, which has completed Phase 2 trials - A Phase 1 clinical trial of AdCOVID in healthy volunteers is expected to commence in the first quarter of 2021 - Immunogenicity and safety data from their Phase 1 clinical trial of AdCOVID Scot Roberts, Chief Scientific Office, Altimune, Inc, USA
10:55	Exhibition Viewing & Networking Break
	SARS-CoV-2 Vaccine Development - Case-studies and Challenges
11:15	SARS-CoV-2 Vaccine Development Challenges & Strategy Li Shi, CEO, Shanghai Zerun Biotechnology, China
11:40	Accelerated development of SARS-CoV-2 Vaccines - CEPI supports cross-cutting programs including the development of biological standards, assays, animal models, epidemiological studies, and diagnostics. - CEPI has initiated 11 partnerships to develop vaccines against this virus - CEPI's future plans in the pandemic control Arun Kumar, Preclinical Vaccine development Lead, CEPI, Norway
12:05	Initial development and proof-of-concept studies for UB-612 vaccine against SARS-CoV-2 - UB-612 consists of eight components rationally designed for induction of high neutralizing antibodies and broad T cell responses against SARS-CoV-2 - Phase 1 trial being completed in Taiwan and additional trials planned worldwide Farshad Guirakhoo, Chief Scientific Officer, COVAXX and VAXXINITY, members of the UBI Group, USA

12:30	Networking Lunch Break
	Pandemic Vaccine Panel and Clinical Trial Results from SARS-CoV-2 Vaccine Manufacturers
13:35	Keynote Panel Discussion: Global Pandemic Vaccine Action Plan in Near- and Long-Term Strategies to Increase the Supply of Pandemic Vaccine to developing economies - The present situation and current challenges - Major approaches to increase supplies of COVID-19 vaccine - Strategies to speed up clinical trials in developing economies Rajinder Kumar Suri, CEO, DCVMN Matthew Downham, PhD, Sustainable Manufacturing Lead, CEPI, United Kingdom Etleva Kadill, Director Supply Division, UNICEF, Denmark Marin Friede, Coordinator, Initiative for Vaccine Research (IVR), WHO, Switzerland Dominique Maugeais, Vaccine Manufacturing Expert, GAVI, Switzerland
14:25	COVAXIN: Latest updates on its development - COVAXIN is an indigenously developed whole virion inactivated SARS-CoV-2 vaccine - Due to the desired attribute of Th1 response, this technology has been coupled with a novel adjuvant to mitigate concerns of Enhanced Respiratory Disease - COVAXIN has been found to be safe and efficacious in a large scale phase 3 clinical trial Raches Ella, Head - Project Lead: SARS-CoV-2 Vaccine, Bharat Biotech, India
14:50	Updates on their current stage of SARS-CoV-2 vaccine development from Zydus Cadila Kapil Maithil, President & Head, Vaccines and Diagnostics, Zydus Cadila, India
15:15	Networking Break
	Fill & Finish and Vaccine Manufacturing in Developing Economies
15:40	Technology Presentation: Reserved for vaccines bioprocessing solution providers
16:05	Manufacturing of Rabies Vaccines: Serum Institute of India - Study of Rabies gives well- developed new purified Vero cell rabies vaccine (Rabivax-S), following all the GMP requirement - We evaluated its safety, toxicity and immunogenicity in post-exposure prophylaxis in clinical trials by IM and ID routes. - This vaccine is good option among the available modern WHO prequalified rabies vaccine Ashish Sahai, Additional Director, Serum Institute of India
16:30	Accelerating Process Development & Commercial Manufacturing of a Novel Vaccine Using DoE as Process Design - Design of Experiments (DoE) as part of QbD in to early-stage process development of vaccine manufacturing - Conventional vs. DoE-based process design & its Merits - Benefits of continual improvement of an existing process for a better improved process
16:55	Chairman's closing remarks and wrap up of Day 1 proceedings

CONFERENCE DAY 2 – 20TH MAY 2021

8:30	Conference Registration
9:00	IMAPAC' Welcome Back Remarks
9:05	Chairman's Opening Remarks
	Vaccine Development and Manufacturing Excellence in Developing Economies
9.10	Advances and Challenges in Vaccines Development and Manufacture in Developing Economies Anh Wartel, Head of Clinical Development, International Vaccine Institute, Korea
9.35	Technology Presentation: Reserved for Vaccines Bioprocessing Solution Providers
10.00	Creating Awareness for the Usage of Adult Vaccines in Developing Economies • Challenges in including adult vaccines in the immunisation program • Key initiatives taken by other developing economies that developing economies can replicate • Initiatives already in place in Indonesia, Thailand, Malaysia and India to increase focus on adult vaccinations
	Networking Break
	Next Generation Platform Technologies and Clinical Trial Results from Next- Gen Pipelines in the Industry
10.40	Future of Vaccinology: mRNA Sanjay Singh, CEO, Gennova Pharmaceuticals, India
11.05	Development of Potent Adjuvanted Respiratory Syncytial Virus Vaccine for Mucosal Delivery Harshad Patil, Scientist, Interactive Research School for Health Affairs, India
11.30	Technology Presentation: Reserved for Vaccines Bioprocessing Solution Providers
11.55	Pneumococcal Vaccine: Biological E. Ltd. Ramesh Mathur, Senior Vice President and Head, Research and Development, Biological E., India
12.20	Networking Lunch Break
	Vaccine Facilities of the Future
13.30	Establishing Sustainable Manufacturing in Low- and Middle-income Countries Matthew Downham, PhD, Sustainable Manufacturing Lead, CEPI, United Kingdom
14.30	Telangana: Vaccine Capital of the World - Hyderabad contributes to around 1/3rd of Global Vaccine Production - 4 out of 5 leading vaccine manufacturers in India are in Hyderabad - The state provides excellent infrastructure for vaccine development and manufacturing Jayesh Ranjan, Principal Secretary, Industries & Commerce (I&C) and Information Technology (IT), Government of Telangana
14.55	Networking Lunch Break
	Fill and Finish and Vaccine Manufacturing in Developing Economies
15: 30	Vaccine Manufacturing Excellence-Process Development, Production and Scale-up
15.55	Bacterial Vaccine Manufacturing and how Bio Farma deals with the COVID-19 Pandemic (transfer technology, campaign production etc) Dea Marsendah, Hib Production, Bio Farma, Indonesia
16.30	Closing Panel Discussion: Challenges and Opportunities of Manufacturing Vaccines in the Developing World on the Bigger Scale
17:30	Chairman's closing remarks and wrap up of Day 2 proceedings
17:45	Conference Ends

EXPLORE OUR NEW VIRTUAL ECOSYSTEM



THE LOBBY

Virtual Event space designed to give immerse feel to attendees as if they are actually attending conference



THE AUDITORIUM

Virtual Auditorium where is the agenda will be hosted (pre-recorded and live presentations)



EXHIBIT HALL

Exhibit Hall where Exhibitors can engage with the conference attendees on their designed virtual booths



BOOTHS

Networking Lounge- where all attendees can interact via group chat and 1:1 private chat via text, audio and video conversations.



HELPDESK

Technical Help Desk available through live chat, call or email for technical and trouble shooting related concerns available to all attendees



LEARNING ZONE

Info Center to connect with organizer for any queries or concerns regarding the event

Explore endless opportunities with our app.
Check out our latest app statistics!



8000+

Attendee interactions facilitated in private 1 on 1 message across 4 events so far



1000+

e-Business cards exchanged



500+

Virtual meet-ups created and attended by our virtual event participants



100+

Private meetings created among participants



100+

Private group chats created

VACCINES WORLD SUMMIT 2021 IS GOING VIRTUAL

CAN I INTERACT WITH THE SPEAKERS DURING THEIR SESSION?

With our event app, you can easily set up questions which the presenters are able to quickly access, in real time. Each presenter is allocated a 15-minute Q&A session, as well. In addition to this, you can also set-up meetings, exchange personal messages, and even create closed discussion groups with the speakers!



HOW DO PARTICIPANTS ENGAGE IN NETWORKING ACTIVITIES?

The event app allows interaction with anyone attending through Virtual Meetups at your own convenient time. Additionally, all speakers will be present to network before and after their sessions to answer questions and interact with the exhibitors. Live Panel discussions and roundtables have been put in places to increase engagement throughout the event. The app also allows more ways to engage before, during and after the conference through live polls, custom discussion topic and 1-1 meetings which you can schedule. Kindly view the Virtual Conference guide for more details!



WILL ATTENDANCE AT VIRTUAL CONFERENCES BE GREATLY IMPACTED?

To ensure participation, we are maintaining the same level of quality of content and discussions for our participants. IMAPAC is putting together a lineup of 50+ speakers, for the 2021 event to provide a thought-provoking experience for our participants.

WHICH PLATFORM WILL I ACCESS THE EVENT ON?

The event link will be embedded on our virtual event platform, ensuring networking and learning is taken care of through one platform. The platform can be accessed either on your desktop or on your phone.



Registration Form

	LIMITED SPECIAL EXPIRES 26TH FEB	EARLY BIRD EXPIRES 16TH APRIL	STANDARD RATES STARTS 17TH APRIL
1 User License (BUY 1 GET 1 FREE) BioPharmas / Academics / Research Institutes/ NGOs	SGD 200	SGD 300	SGD 500
3 User License (BUY 3 GET 5 FREE) BioPharmas / Academics / Research Institutes/ NGOs	SGD 600	SGD 900	SGD 1500
2-User License Solution Providers/ CMO/CDMOs/ Distributors	SGD 3595 BUY 1 GET 1 FREE	SGD 3595 BUY 1 GET 1 FREE	SGD 3595

- **End User Company Profiles:** Asian and International Biopharmas, BIG Pharmas, Academic & Research Institutes
- **Solution Provider Profiles:** Service/Technology Providers, Consulting Companies, CROs, CMOs, Logistics Providers
- **INNER CIRCLE:** If you have a written referral from one of our speakers, you are entitled 15% discount off the rate that is applicable to you. To qualify, please ask the speaker to drop us an email rima.karan@imapac.com

EVENT VENUE



19-20 MAY
Virtual Conference

YOUR DETAILS

Name _____
Job Title _____ Organization _____
Address _____
Postcode _____ Country _____
Tel _____ Fax _____
Email _____
Your primary business _____
Authorising Manager _____ Authorising manager signature _____
By signing and returning this form, you are accepting our terms and conditions.

PAYMENT DETAILS

Payment is due immediately upon receipt of this registration form if you pay by credit card or 3 working days after your receipt of payment notification. Non-credit card payment will incur an additional US\$100 (Bank handling fee)

I want to pay ☐ Credit Card ☐ Non-credit card and add US\$100 bank handling fee

Online credit card payment:

Please register at: https://www.imapac.com/en/business_conferences/vaccine-world-summit-india/#register

Offline credit card payment:

☐ Visa ☐ MasterCard ☐ American Express

Name on Card _____ Card Number _____
Expiry Date (MM/YY) _____ CVC Code _____ Signature _____

☐ Bank transfer: Payment by bank transfer must quote delegate name and conference name.
For bank details & swift code, it will be emailed to you as part of the invoice.

☐ Cheque payment: Crossed cheque payable to IMAPAC Pte Ltd, and mail it in a sealed envelope to **IMAPAC Pte Ltd, 133 Cecil Street, #05-02A Keck Seng Tower, Singapore 069535**

3 Easy Ways to Register:

Online

To book online, visit:

W:https://www.imapac.com/en/business_conferences/vaccine-world-summit-india/#register

Telephone

To register over the phone, please call us on

+65 3109 0127

By Cheque

By cheque made payable to:

IMAPAC PTE. LTD.

Send with this booking form to:

IMAPAC PTE. LTD.
133 Cecil Street, #05-02A Keck Seng Tower, Singapore 069535

Group Booking

Send your team & save more!

3 delegates **SAVE 10%**

5 delegates **SAVE 20%**

Call **+65 3109 0127**

TERMS & CONDITIONS:

- Full payment is due upon registration if you pay by credit card, or 3 working days after receipt of invoice.
- Registration will not be confirmed until full payment has been received.
- Unpaid registration will be billed 50% of the registration fee if you do not attend the event. A copy of the conference documentation will be mailed to you.
- The registration fee includes refreshments, lunches, cocktails and full conference documentation. The conference fee does not include hotel accommodation.
- Staff at the event will request a credit card guarantee for delegates without proof of payment.

CANCELLATION & SUBSTITUTION POLICY:

- Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit note to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee.
- A substitution from the same organisation can be made at any time in writing at no extra charge.
- In the event that IMAPAC cancels a conference, payments received at the cancellation date will be credited towards attendance at a future conference or in the event of postponement by IMAPAC, towards the rescheduled date.
- Credit notes remain valid for twelve months.

CHANGES TO CONFERENCE & AGENDA:

IMAPAC reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers for an event. IMAPAC is not responsible for any loss or damage as a result of substitution, alteration, postponement or cancellation of an event due to causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

In the event that a conference is cancelled, IMAPAC is not liable for any costs incurred by delegates in connection with their attendance. Control to alter the content and timing of the programme, venue or the identity of the speakers without any liability to the delegates. Changes to the agenda will be updated on our website as soon as possible.

DATA PROTECTION: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to reputable third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: data@imapac.com.

CONTACT US

SPONSORSHIP & SPEAKING OPPORTUNITIES



Pavithra Selvam

Conference Producer

T: +65 3109 0225

Email: pavithra.selvam@imapac.com

REGISTRATION & MEDIA



Rima Karan

Marketing Executive

T: +65 8742 7502

Email: rima.karan@imapac.com

GENERAL MANAGER



Sumukhi Sreevatsan

GM

T: +65 3109 0126

Email: sumukhi.sreevatsan@imapac.com



133 Cecil Street, #05-02,
Keck Seng Tower,
Singapore 069535

7912 Makati Ave, Makati,
Metro Manila, Philippines



+65 3109 0121
+65 6722 0649



info@imapac.com



www.imapac.com

2021 CALENDAR OF EVENTS

FEBRUARY



2 - 4 February 2021 | Virtual



2 - 4 February 2021 | Virtual

MARCH



16 - 17 March 2021 | Virtual



16 - 17 March 2021 | Virtual



16 - 17 March 2021 | Virtual

MAY



19 - 20 May 2021 | Virtual

JUNE



23 - 24 June 2021 | Virtual

AUGUST



24 - 26 Aug 2021 | Virtual

SEPTEMBER



14 - 16 September 2021 | Virtual

OCTOBER



27 - 28 October 2021 | Virtual



26 - 28 October 2021 | Virtual

NOVEMBER



9 - 11 November 2021 | Virtual



rima.karan@imapac.com
T: +65 3109 0225

[REGISTER](#)